Aegle Therapeutics raises $4 million to fund a groundbreaking stem cell exosome clinical trial to treat the orphan disease, Dystrophic Epidermolysis Bullosa.
BOSTON and MIAMI, Jan. 7, 2020 — Aegle Therapeutics Corp., a first in class biotechnology company isolating extracellular vesicles, including exosomes (“EVs”), secreted by mesenchymal stem cells as therapy, announced the closing of a $4M financing. Aegle’s platform technology is initially being developed to treat dystrophic epidermolysis bullosa (“DEB”), a rare pediatric skin blistering disorder. [Read more…]